Sebetralstat is a small molecule commercialized by Kalvista Pharmaceuticals, with a leading Pre-Registration program in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). According to Globaldata, it is involved in 10 clinical trials, of which 6 were completed, 3 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Sebetralstats valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Sebetralstat is expected to reach an annual total of $718 mn by 2034 globally based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Sebetralstat Overview
Sebetralstat (KVD-900) is under development for the treatment of hereditary angioedema. The drug candidate is administered through oral route in the form of the tablet. It acts by targeting plasma kallikrein.
Kalvista Pharmaceuticals Overview
Kalvista Pharmaceuticals (Kalvista) is a biopharmaceutical company that primarily focuses on the discovery, development, and commercialization of oral protease inhibitor drugs. The company focuses on addressing the unmet needs of people living with hereditary angioedema (HAE), a rare genetic disease. The companys product pipeline includes sebetralstat, oral factor Xlla and KVD001. Kalvista’s pipeline candidates treat hereditary angioedema, prophylaxis in hereditary angioedema, thrombosis inflammation and diabetic macular edema. The company’s operations focuses on the development of novel oral, small molecule protease inhibitors as potential treatments for a range of diseases. Kalvista is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$140.4 million in FY2024, compared to an operating loss of US$110.9 million in FY2023. The net loss of the company was US$126.6 million in FY2024, compared to a net loss of US$92.9 million in FY2023.
For a complete picture of Sebetralstats valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
